- $138.44bn
- $190.12bn
- $62.58bn
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal (updated)
Commission's appeal against COVID vaccine contract disclosures should be dismissed, court adviser says (updated)
Commission appeal in COVID vaccine contract case should be dismissed, EU court adviser says
Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal
Pfizer CEO warns German investment at risk over drug pricing policies (updated)
Pfizer CEO warns German investment at risk over drug pricing policies
Focus: Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon
U.S. RESEARCH ROUNDUP- Datadog, Eli Lilly, Oracle
Pentagon casts dark cloud over China biotech
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Major deals involving US drugmakers and biotechs over the past decade
Street View: Pfizer's monthly obesity shot awaits key late-stage study results
Corrected: US FDA approves Pfizer's bleeding disorder drug for children
Brief: U.S. FDA Approves Pfizer’S Hympavzi For The Treatment Of Two Additional Hemophilia A Or B Patient Populations With Significant Medical Need
Media: Pfizer-partnered obesity drugmaker Hangzhou Sciwind Biosciences eyes deals outside China- Bloomberg News
Brief: Pfizer Says Vesper-1 Shows Nearly 16% Weight Loss At 32 Weeks On 2.4 Mg Weekly Berobenatide
Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial